Seagen shares are trading higher after the company and Astellas Pharma announced PADCEV and KEYTRUDA significantly improve overall survival and progression-free survival in patients with previously untreated advanced bladder cancer in pivotal Phase 3 EV-302 trial.
Portfolio Pulse from Benzinga Newsdesk
Seagen announced that its PADCEV and KEYTRUDA drugs significantly improved overall survival and progression-free survival in patients with previously untreated advanced bladder cancer in a pivotal Phase 3 EV-302 trial. This news has led to a rise in Seagen's share price.
September 22, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seagen's share price is trading higher following the positive results from the Phase 3 EV-302 trial of PADCEV and KEYTRUDA for advanced bladder cancer.
The positive results from the Phase 3 trial of Seagen's drugs PADCEV and KEYTRUDA for advanced bladder cancer have led to increased investor confidence, resulting in a rise in the company's share price. This news is highly relevant to Seagen as it directly pertains to the company's products and their efficacy, which can significantly impact the company's financial performance and market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100